Switchpoint Bio Raises €4.75Mn in Pre-Seed Funding to Develop Blood-Based Epigenomic Platform

The funding round includes a €4.48 million ($5 million) investment from Treehouse Delmar Investments. Switchpoint Bio came out of stealth earlier this year.

“Drug developers need to know not only whether a patient responds, but what biology changed, what persisted and why. Our goal is to make these biological switchpoints visible from a routine blood sample, repeatedly and at the scale required for drug development,” said Samuel Myllykangas, PhD, co-founder and CEO of Switchpoint Bio.

“We take a long-term view, backing science we believe can genuinely change how disease is understood and treated. Switchpoint Bio brings together exceptional scientific talent with a real path to turning breakthrough biology into evidence that helps patients, and we’re proud to support that work,” said Dave Proctor of Treehouse Delmar Investments.

Switchpoint Bio was founded in 2025 by Samuel Myllykangas, PhD, and Jason Buenrostro, PhD. The two founders previously worked together on developing DNA sequencing technologies at Stanford University.

Buenrostro is a MacArthur Fellow and professor at Harvard University. He also leads the Epigenomics Program at the Broad Institute of MIT and Harvard. He is known for developing ATAC-seq, a technology used to study changes in gene activity.

Myllykangas previously built and expanded Blueprint Genetics, a company that was acquired by Quest Diagnostics in 2020.

The founding team also includes three other members: Niilo Färkkilä, PhD, who serves as Chief Commercial Officer; Jussi Paananen, PhD, who is the Chief Technology Officer; and Mitja Kurki, PhD, who works as a Scientific Advisor.

Switchpoint Bio is developing a blood-based epigenomic platform to help drug developers understand how diseases and treatments affect the human body. The technology aims to provide a clearer picture of these biological changes and support the development of new medicines.

Read Also- DCAI Secures €67Mn Investment from Netcompany and EIFO to Expand Denmark’s AI Infrastructure